Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000963611 | Stomach | CAG with IM | response to toxic substance | 44/1050 | 262/18723 | 5.73e-11 | 1.13e-08 | 44 |
GO:000919911 | Stomach | CAG with IM | ribonucleoside triphosphate metabolic process | 24/1050 | 89/18723 | 7.02e-11 | 1.34e-08 | 24 |
GO:000914211 | Stomach | CAG with IM | nucleoside triphosphate biosynthetic process | 23/1050 | 85/18723 | 1.62e-10 | 2.98e-08 | 23 |
GO:200123311 | Stomach | CAG with IM | regulation of apoptotic signaling pathway | 52/1050 | 356/18723 | 2.17e-10 | 3.85e-08 | 52 |
GO:000683911 | Stomach | CAG with IM | mitochondrial transport | 42/1050 | 254/18723 | 2.58e-10 | 4.44e-08 | 42 |
GO:005254711 | Stomach | CAG with IM | regulation of peptidase activity | 61/1050 | 461/18723 | 3.60e-10 | 6.00e-08 | 61 |
GO:000914111 | Stomach | CAG with IM | nucleoside triphosphate metabolic process | 26/1050 | 112/18723 | 4.23e-10 | 6.83e-08 | 26 |
GO:005254811 | Stomach | CAG with IM | regulation of endopeptidase activity | 58/1050 | 432/18723 | 5.62e-10 | 8.56e-08 | 58 |
GO:000612011 | Stomach | CAG with IM | mitochondrial electron transport, NADH to ubiquinone | 17/1050 | 51/18723 | 1.14e-09 | 1.48e-07 | 17 |
GO:001603211 | Stomach | CAG with IM | viral process | 55/1050 | 415/18723 | 2.54e-09 | 2.88e-07 | 55 |
GO:200123411 | Stomach | CAG with IM | negative regulation of apoptotic signaling pathway | 37/1050 | 224/18723 | 3.09e-09 | 3.36e-07 | 37 |
GO:003297011 | Stomach | CAG with IM | regulation of actin filament-based process | 53/1050 | 397/18723 | 3.83e-09 | 3.86e-07 | 53 |
GO:003310811 | Stomach | CAG with IM | mitochondrial respiratory chain complex assembly | 22/1050 | 93/18723 | 6.37e-09 | 6.07e-07 | 22 |
GO:001025711 | Stomach | CAG with IM | NADH dehydrogenase complex assembly | 17/1050 | 57/18723 | 7.82e-09 | 7.19e-07 | 17 |
GO:003298111 | Stomach | CAG with IM | mitochondrial respiratory chain complex I assembly | 17/1050 | 57/18723 | 7.82e-09 | 7.19e-07 | 17 |
GO:001905811 | Stomach | CAG with IM | viral life cycle | 45/1050 | 317/18723 | 8.82e-09 | 7.70e-07 | 45 |
GO:000915011 | Stomach | CAG with IM | purine ribonucleotide metabolic process | 48/1050 | 368/18723 | 4.36e-08 | 3.32e-06 | 48 |
GO:000616311 | Stomach | CAG with IM | purine nucleotide metabolic process | 50/1050 | 396/18723 | 6.52e-08 | 4.63e-06 | 50 |
GO:000925911 | Stomach | CAG with IM | ribonucleotide metabolic process | 48/1050 | 385/18723 | 1.76e-07 | 1.16e-05 | 48 |
GO:004586111 | Stomach | CAG with IM | negative regulation of proteolysis | 45/1050 | 351/18723 | 1.90e-07 | 1.24e-05 | 45 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa051714 | Colorectum | MSS | Coronavirus disease - COVID-19 | 108/1875 | 232/8465 | 6.50e-17 | 1.67e-15 | 1.03e-15 | 108 |
hsa051715 | Colorectum | MSS | Coronavirus disease - COVID-19 | 108/1875 | 232/8465 | 6.50e-17 | 1.67e-15 | 1.03e-15 | 108 |
hsa051716 | Colorectum | MSI-H | Coronavirus disease - COVID-19 | 91/797 | 232/8465 | 2.21e-35 | 3.58e-33 | 3.00e-33 | 91 |
hsa051717 | Colorectum | MSI-H | Coronavirus disease - COVID-19 | 91/797 | 232/8465 | 2.21e-35 | 3.58e-33 | 3.00e-33 | 91 |
hsa0517122 | Liver | Cirrhotic | Coronavirus disease - COVID-19 | 136/2530 | 232/8465 | 3.28e-20 | 1.82e-18 | 1.12e-18 | 136 |
hsa046102 | Liver | Cirrhotic | Complement and coagulation cascades | 48/2530 | 86/8465 | 4.41e-07 | 5.44e-06 | 3.35e-06 | 48 |
hsa05133 | Liver | Cirrhotic | Pertussis | 37/2530 | 76/8465 | 4.17e-04 | 2.57e-03 | 1.58e-03 | 37 |
hsa04936 | Liver | Cirrhotic | Alcoholic liver disease | 60/2530 | 142/8465 | 1.07e-03 | 5.85e-03 | 3.61e-03 | 60 |
hsa0517132 | Liver | Cirrhotic | Coronavirus disease - COVID-19 | 136/2530 | 232/8465 | 3.28e-20 | 1.82e-18 | 1.12e-18 | 136 |
hsa046103 | Liver | Cirrhotic | Complement and coagulation cascades | 48/2530 | 86/8465 | 4.41e-07 | 5.44e-06 | 3.35e-06 | 48 |
hsa051331 | Liver | Cirrhotic | Pertussis | 37/2530 | 76/8465 | 4.17e-04 | 2.57e-03 | 1.58e-03 | 37 |
hsa049361 | Liver | Cirrhotic | Alcoholic liver disease | 60/2530 | 142/8465 | 1.07e-03 | 5.85e-03 | 3.61e-03 | 60 |
hsa0517142 | Liver | HCC | Coronavirus disease - COVID-19 | 167/4020 | 232/8465 | 1.50e-14 | 4.19e-13 | 2.33e-13 | 167 |
hsa049362 | Liver | HCC | Alcoholic liver disease | 89/4020 | 142/8465 | 1.73e-04 | 8.53e-04 | 4.75e-04 | 89 |
hsa046104 | Liver | HCC | Complement and coagulation cascades | 57/4020 | 86/8465 | 3.19e-04 | 1.45e-03 | 8.04e-04 | 57 |
hsa051332 | Liver | HCC | Pertussis | 48/4020 | 76/8465 | 4.17e-03 | 1.27e-02 | 7.06e-03 | 48 |
hsa0517152 | Liver | HCC | Coronavirus disease - COVID-19 | 167/4020 | 232/8465 | 1.50e-14 | 4.19e-13 | 2.33e-13 | 167 |
hsa049363 | Liver | HCC | Alcoholic liver disease | 89/4020 | 142/8465 | 1.73e-04 | 8.53e-04 | 4.75e-04 | 89 |
hsa046105 | Liver | HCC | Complement and coagulation cascades | 57/4020 | 86/8465 | 3.19e-04 | 1.45e-03 | 8.04e-04 | 57 |
hsa051333 | Liver | HCC | Pertussis | 48/4020 | 76/8465 | 4.17e-03 | 1.27e-02 | 7.06e-03 | 48 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
C2 | SNV | Missense_Mutation | novel | c.1050N>A | p.Met350Ile | p.M350I | P06681 | protein_coding | tolerated(0.19) | possibly_damaging(0.511) | TCGA-A2-A0CX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
C2 | SNV | Missense_Mutation | | c.346G>A | p.Glu116Lys | p.E116K | P06681 | protein_coding | tolerated(0.06) | benign(0.215) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
C2 | SNV | Missense_Mutation | novel | c.803N>G | p.Asn268Ser | p.N268S | P06681 | protein_coding | tolerated(0.77) | benign(0) | TCGA-AC-A3QQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
C2 | SNV | Missense_Mutation | rs567227615 | c.256N>T | p.Pro86Ser | p.P86S | P06681 | protein_coding | tolerated(0.13) | benign(0.028) | TCGA-BH-A18Q-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
C2 | SNV | Missense_Mutation | rs764034564 | c.185N>A | p.Arg62Gln | p.R62Q | P06681 | protein_coding | deleterious(0.02) | benign(0.366) | TCGA-D8-A1XQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
C2 | insertion | Frame_Shift_Ins | novel | c.2056_2057insCATGTCTGGCTAATTTTTGTATTTTT | p.Glu686AlafsTer21 | p.E686Afs*21 | P06681 | protein_coding | | | TCGA-AO-A0JB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD |
C2 | deletion | Frame_Shift_Del | novel | c.729_739delNNNNNNNNNNN | p.Lys244ProfsTer22 | p.K244Pfs*22 | P06681 | protein_coding | | | TCGA-BH-A1F6-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
C2 | SNV | Missense_Mutation | rs766407308 | c.394C>T | p.Arg132Cys | p.R132C | P06681 | protein_coding | deleterious(0.02) | benign(0.012) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
C2 | SNV | Missense_Mutation | | c.1315N>G | p.Leu439Val | p.L439V | P06681 | protein_coding | tolerated(0.43) | benign(0.26) | TCGA-DS-A1OC-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | gemcitabine | SD |
C2 | SNV | Missense_Mutation | | c.811C>G | p.Leu271Val | p.L271V | P06681 | protein_coding | tolerated(0.24) | benign(0) | TCGA-LP-A4AV-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |